The mission of the Developmental Therapeutics Program, at the Alabama Center for Childhood Cancer and Blood Disorders, is to identify and develop new therapies for children and young adults with cancer. Our ultimate goal is to improve the cure rate of pediatric cancers while also decreasing immediate and long-term side effects experienced by children undergoing treatment. Patients referred to the Developmental Therapeutics Program typically have recurrent or refractory malignancies that have failed standard therapies. Other patients may be diagnosed with rare tumors for which no effective therapies have been established.
As one of only 21 premier pediatric oncology programs in the country that were selected through a peer review by the Children’s Oncology Group Phase 1 and Pilot Consortium, we are able to provide patients access to innovative therapies not widely available. The Developmental Therapeutics Program is also a member of the Neurofibromatosis Consortium, the Head Start Consortium, and Sarcoma Alliance for Research through Collaboration (SARC). Additionally, we work with the pharmaceutical industry and with the diverse scientific community at the University of Alabama at Birmingham (UAB). Studies currently open and accruing patients are listed below.
Ongoing collaborations include bench to bedside clinical trials of promising new agents or combinations of agents to treat pediatric cancers including brain tumors, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and leukemia. By combining the innovation and expertise of the UAB Division of Pediatric Hematology-Oncology, Children’s of Alabama, and researchers from UAB and around the world, the Developmental Therapeutics Program offers cutting-edge therapies and state-of-the-art care while helping to advance the treatment of pediatric cancers for generations to come.
For more information, contact: Developmental Therapeutics Research Nurse Manager Bridget Tate, RN MSN at 205-638-2984 or email@example.com
Alyssa T. Reddy, M.D.
Professor of Pediatrics, Neurology, and Surgery
Director, Neuro-Oncology and Developmental Therapeutics
UAB Division of Pediatric Hematology-Oncology
Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children with Recurrent Supratentorial Brain Tumors (this would link to neuro-onc page)
UAB 1472 HSV G207 Study Synopsis for Healthcare Professionals (PDF)
UAB 1472 HSV G207 Patient and Family Summary (PDF)
MEK162 — Phase I-II Study of MEK 162 for Children with Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
ADVL1212 — A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma.
ADVL1217 A Phase 1 Study of AZD1775 (MK-1775, IND#116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas
ADVL1312 — A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
ADVL1411 — A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
ADVL1412 — A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
ADVL1414 — A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
ADVL1416 — A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors
ADVL1513 — A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
ADVL1515 — A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors.